Dr. Reddy's Laboratories

NYSE: RDY
$52.46
-$0.01 (0.0%)
Closing price June 2, 2020
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
Carl Sullivan
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
Carl Sullivan
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
Chris Lange
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
Carl Sullivan
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting the stock instead of the...
Chris Lange
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
Carla Baranauckas
Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.
Paul Ausick
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin viable going...
Chris Lange
Monday's top analyst upgrades, downgrades and initiations included Alibaba, AT&T, Bank of America, BlackBerry, Boeing, Citigroup, Cloudflare, DocuSign, Lululemon Athletica, Marvell Technology,...
Jon C. Ogg
India has been one of the best growth economies measured by gross domestic product for some time, but the secular growth opportunity has faced multiple setbacks in 2018 that may persist,
Jon C. Ogg
Everyone knows that investors will pay up to chase growth, and it is quite possible that India might be one of the best growth stories in the world for 2018 and beyond.
Jon C. Ogg
The include Abercrombie & Fitch, Arch Coal, Baker Hughes, BioMarin Pharmaceutical, Gilead Sciences, Hasbro and Snap.
Jon C. Ogg
The top analyst upgrades, downgrades and other research calls from Monday include Applied Materials, Cerner, Cisco Systems, Johnson & Johnson, Level 3 Communications and Salesforce.com.
Jon C. Ogg
Stocks got a big boost on news that Janet Yellen is talking down the Federal Reserve’s desire to hike interest rates no matter what. Investors in 2016 have used rallies a chance to sell, with a...
Jon C. Ogg
Source: Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Wednesday morning.Annaly Capital Management Inc. (NYSE:...
Jon C. Ogg